WEDNESDAY, Dec. 22 (HealthDay News) -- NFKBIA deletion appears to promote tumor growth in glioblastomas that do not have epidermal growth factor receptor (EGFR) alterations, according to research published online Dec. 22 in the New England Journal of Medicine.
Markus Bredel, M.D., Ph.D., of the University of Freiburg in Germany, and colleagues analyzed 790 glioblastomas for deletions, mutations, or NFKBIA or EGFR expression and studied the tumor-suppressor activity of NFKBIA in tumor cell culture. They compared the molecular results with glioblastoma outcomes in 570 patients.
The researchers determined that NFKBIA was not mutated, but was often deleted in glioblastomas, particularly in nonclassical subtypes of the disease. Poorer outcomes were associated with deletion and low expression of NFKBIA, and patients with NFKBIA had outcomes similar to those with EGFR amplification.
"Deletion of NFKBIA has an effect that is similar to the effect of EGFR amplification in the pathogenesis of glioblastoma and is associated with comparatively short survival," the authors write.
Several authors disclosed financial relationships with pharmaceutical and diagnostic companies, including Castle Biosciences, Genentech/Roche, and Schering Plough.
Abstract
Full Text (subscription or payment may be required)
